New drug combo shows promise in tough pancreatic cancer

NCT ID NCT07026279

Ongoing Disease control Sponsor: Amplia Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called narmafotinib, taken as a daily pill, together with a standard chemotherapy regimen (mFOLFIRINOX) in people whose pancreatic cancer has spread. The trial has two parts: first, finding a safe dose, then comparing two doses in 20 people each. The goal is to see if the combination is safe and effective, and to pick the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: narmafotinib (a FAK inhibitor) combined with modified FOLFIRINOX chemotherapy
What this could lead to: If successful, this could lead to a new treatment option that helps control metastatic pancreatic cancer and improves survival.
What could go wrong: This is an early-phase trial with only 67 participants, so results may not apply to all patients. The drug combination may cause significant side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER METASTATIC

Contacts and locations

Show contact details

Locations

Epworth Healthcare

Richmond, Victoria, 3121, Australia
GenesisCare

St Leonards, New South Wales, 2065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.